SCHEMBL25220232

SCHEMBL25220232

COC[C@H](C(=O)Cl)N1C(=O)c2ccccc2C1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.49
GAA P10253 1/20 0.49
POLB P06746 4/20 0.48
TP53 P04637 2/20 0.48
KDM4E B2RXH2 1/20 0.48
GLA P06280 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
HPGD P15428 1/20 0.48
ALOX12 P18054 1/20 0.48
NFKB1 P19838 1/20 0.48
APEX1 P27695 1/20 0.48
MAPK1 P28482 1/20 0.48
HSD17B10 Q99714 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
KMT2A Q03164 1/20 0.45
MAPT P10636 1/20 0.43
HSD11B1 P28845 1/20 0.43
TNF P01375 2/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30447260 1.00 ALDH1A1 (0.49) ALDH1A1GAAPOLBTP53KDM4E
SCHEMBL25270229 1.00 ALDH1A1 (0.49) ALDH1A1GAAPOLBTP53KDM4E
SCHEMBL25261569 0.86 ALDH1A1 (0.62) ALDH1A1GAAPOLBTP53KDM4E
SCHEMBL14680989 0.86 ALDH1A1 (0.62) ALDH1A1GAAPOLBTP53KDM4E
SCHEMBL14681023 0.84 ALDH1A1 (0.49) ALDH1A1GAAPOLBTP53KDM4E
SCHEMBL22365795 0.84 ALDH1A1 (0.46) ALDH1A1GAAPOLBTP53KDM4E
SCHEMBL6243248 0.82 ALDH1A1 (0.53) ALDH1A1GAAPOLBTP53KDM4E
SCHEMBL32691108 0.82 ALDH1A1 (0.53) ALDH1A1GAAPOLBTP53KDM4E
SCHEMBL29459236 0.82 ALDH1A1 (0.53) ALDH1A1GAAPOLBTP53KDM4E
SCHEMBL5422287 0.79 ALDH1A1 (0.60) ALDH1A1GAAPOLBTP53KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250320234-A1 LONP1 INHIBITOR COMPOUNDS, USES AND METHODS PRETZEL THERAPEUTICS, INC. (US) 2025-10-16 US disclosed
WO-2023107487-A1 LONP1 INHIBITOR COMPOUNDS, USES AND METHODS PRETZEL THERAPEUTICS, INC. (US) 2023-06-15 WO disclosed
WO-2023107487-A1 LONP1 INHIBITOR COMPOUNDS, USES AND METHODS PRETZEL THERAPEUTICS, INC. (US) 2023-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250320234-A1 LONP1 INHIBITOR COMPOUNDS, USES AND METHODS LONP1, NLN, ACAT1 ALDH1A1 1527/4885GAA 132/4885POLB 320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.